


# BRAZIL

## Cutaneous and mucosal Leishmaniasis 2018

Incidence (100,000 pop.) **15.8**  
 Transmission **Very Intense**  
 Triennium Leishmaniasis Composite Indicator (TLCIc 2016-2018)



### TLCIc triennium (2016-2018)



\*The MoH reported 1305 cases from unknown municipalities that were not included in the leishmaniasis composite indicator analysis.

### Occurrence

# 16432

NEW CASES

15632 cutaneous (95.1%)

800 mucosal (4.9%)



### AGE GROUP

2.8% < 5 Y/O  
 3.2% ≥ 5 < 10 Y/O  
 93.1% > 10 Y/O  
 0.9% Unspecified

**6%** children under 10 years old



### GENDER

74.2% Male  
 25.8% Female

**70.1%** men over 10 years old



### CROSS-BORDER

Shares borders with **10** countries in **588** municipalities

**17%** of the cases at the borders



### SURVEILLANCE AND CONTROL

**49.8%** of the population in transmission areas

**Decrease** of the CL % in children under 10 Y/O compared to the previous year (Targets of the 2017-2022 Plan of Action)



### LEISHMANIA SPECIES

*L. amazonensis*  
*L. braziliensis*  
*L. guyanensis*  
*L. lainsoni*  
*L. lindenbergi*  
*L. naiffi*  
*L. shawi*



### LUTZOMYIA VECTORS

*L. flaviscutellata*, *L. whitmani*, *L. neivai*, *L. migonei*, *L. intermedia*, *L. complexa*, *L. wellcomei*, *L. davisii*, *L. fischeri*, *L. pessoai*, *L. umbratillis*, *L. ubiquitalis*, *L. ayrozai*, *L. paraensis*, *L. amazonensis*, *L. salesi*, *L. shawi*



### PATIENT ASSISTANCE

Laboratory confirmation: **82.3%**

Cure rate: **72.4%**

% of cured patients among the treated: **75.4%**



### AVAILABLE MEDICINE

Meglumine Antimoniate

Amphotericin B deoxycholate

Amphotericin B Liposomal

Pentamidine isethionate

#### Source:

SisLeish - PAHO/WHO - Data provided by the Ministries of Health - National Leishmaniasis Programs  
 Accessed on: 01 November 2019.

N/I: No information available; Y/O: years old